Global Recombinant Human Coagulation Factor IX Market Growth 2025-2031
Description
The global Recombinant Human Coagulation Factor IX market size is predicted to grow from US$ 574 million in 2025 to US$ 716 million in 2031; it is expected to grow at a CAGR of 3.7% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Recombinant human coagulation factor IX is a drug produced by genetic recombination technology, mainly used to treat hemophilia B (i.e. congenital coagulation factor IX deficiency). Its function is to supplement the coagulation factor IX that is lacking in the patient's body to help control and prevent bleeding. The drug is a colorless and clear solution after reconstitution. It is suitable for daily bleeding management and perioperative management of hemophilia B patients, but is not suitable for the treatment of other types of coagulation factor deficiency or conditions related to the anticoagulant effect of coumarin.
United States market for Recombinant Human Coagulation Factor IX is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Recombinant Human Coagulation Factor IX is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Recombinant Human Coagulation Factor IX is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Recombinant Human Coagulation Factor IX players cover Grifols, Biogen, Octapharma, Baxter, Cusabio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Recombinant Human Coagulation Factor IX Industry Forecast” looks at past sales and reviews total world Recombinant Human Coagulation Factor IX sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Human Coagulation Factor IX sales for 2025 through 2031. With Recombinant Human Coagulation Factor IX sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human Coagulation Factor IX industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Human Coagulation Factor IX landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Human Coagulation Factor IX portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Human Coagulation Factor IX market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human Coagulation Factor IX and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human Coagulation Factor IX.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Coagulation Factor IX market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
250 IU/Bottle
500 IU/Bottle
1000 IU/Bottle
2000 IU/Bottle
Segmentation by Application:
Adult Patients
Child Patients
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Grifols
Biogen
Octapharma
Baxter
Cusabio
Sanofi
Cayman
NovoPro Bioscience
Sino Biological
Bio-Techne
IDELVION
Hualan Bio
Shuyang
ChinaBiologic
Diagbio
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Human Coagulation Factor IX market?
What factors are driving Recombinant Human Coagulation Factor IX market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Human Coagulation Factor IX market opportunities vary by end market size?
How does Recombinant Human Coagulation Factor IX break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Recombinant human coagulation factor IX is a drug produced by genetic recombination technology, mainly used to treat hemophilia B (i.e. congenital coagulation factor IX deficiency). Its function is to supplement the coagulation factor IX that is lacking in the patient's body to help control and prevent bleeding. The drug is a colorless and clear solution after reconstitution. It is suitable for daily bleeding management and perioperative management of hemophilia B patients, but is not suitable for the treatment of other types of coagulation factor deficiency or conditions related to the anticoagulant effect of coumarin.
United States market for Recombinant Human Coagulation Factor IX is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Recombinant Human Coagulation Factor IX is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Recombinant Human Coagulation Factor IX is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Recombinant Human Coagulation Factor IX players cover Grifols, Biogen, Octapharma, Baxter, Cusabio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Recombinant Human Coagulation Factor IX Industry Forecast” looks at past sales and reviews total world Recombinant Human Coagulation Factor IX sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Human Coagulation Factor IX sales for 2025 through 2031. With Recombinant Human Coagulation Factor IX sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human Coagulation Factor IX industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Human Coagulation Factor IX landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Human Coagulation Factor IX portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Human Coagulation Factor IX market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human Coagulation Factor IX and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human Coagulation Factor IX.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Coagulation Factor IX market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
250 IU/Bottle
500 IU/Bottle
1000 IU/Bottle
2000 IU/Bottle
Segmentation by Application:
Adult Patients
Child Patients
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Grifols
Biogen
Octapharma
Baxter
Cusabio
Sanofi
Cayman
NovoPro Bioscience
Sino Biological
Bio-Techne
IDELVION
Hualan Bio
Shuyang
ChinaBiologic
Diagbio
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Human Coagulation Factor IX market?
What factors are driving Recombinant Human Coagulation Factor IX market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Human Coagulation Factor IX market opportunities vary by end market size?
How does Recombinant Human Coagulation Factor IX break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
110 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Wet Waste Compactor by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Wet Waste Compactor by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
